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Abstract
Background: Autosomal recessive hereditary spastic paraplegia (ARHSP) with thin corpus callosum (TCC) is a
complicated form of hereditary spastic paraplegia, characterized by progressive spastic paraplegia, weakness of
the lower extremities and is usually accompanied by mental retardation. Mutations in the Spastic Paraplegia gene
11 (SPG11) account for a large proportion of ARHSP-TCC cases worldwide.
Case presentation: We describe a Chinese family with ARHSP-TCC. Two daughters of this family presented with
a spastic gait and cognitive impairment. Brain imaging of the index patient revealed a thin corpus callosum. We
performed detailed physical and auxiliary examinations and were able to exclude acquired causes of spastic paraplegia.
To determine the causative mutation, we took a candidate gene approach and screened the coding sequence and some
flanking intronic sequence of SPG11 by direct Sanger sequencing. We identified two novel compound heterozygous
mutations in SPG11 in affected individuals (c.1551_1552delTT, p.Cys518SerfsTer39 and c.5867-1G > T (IVS30-1G > T), p.
Thr1956ArgfsTer15). Bioinformatic analysis predicts that these mutations would lead to a loss of protein function due to
the truncation of the SPG11 protein.
Conclusions: The results of this case report indicate a broader approach to include screening for SPG11 mutations in
ARHSP-TCC patients. Our findings enrich the phenotypic spectrum of SPG11 mutations.
Keywords: Autosomal recessive hereditary spastic paraplegia with thin corpus callosum (ARHSP-TCC), SPG11,
Gene mutation, Heterozygous mutations
Background
Hereditary spastic paraplegia (HSP) is a kind of neurode-
generative disease characterized by progressive weakness
and spasticity of the lower limbs. Depending on the mode
of inheritance, it can be classified as autosomal dominant,
autosomal recessive or X-linked. In complicated forms,
additional neurological signs, such as ataxia, mental retard-
ation, epilepsy, peripheral neuropathies, are present [1].
HSP with Thin Corpus Callosum (HSP-TCC) is one of the
most common complicated forms of autosomal recessive
hereditary spastic paraplegia (ARHSP). ARHSP-TCC is
most commonly caused by mutations in the spastic para-
plegia 11 (SPG11) gene [2]. SPG11 maps to chromosome
15q21, encodes a 2443 amino acid protein, SPATACSIN,
and is widely expressed in the nervous system, particularly
in the neurons of the cerebellum and cerebral cortex [3].
Here, we report a Chinese HSP-TCC non-consanguineous
family whose affected family members possess two com-
pound heterozygous mutations in SPG11. These results
implicate a need for wider screening of SPG11 mutations
in ARHSP-TCC patients.
Case presentation
Index Patient (II:3) is a 26-year old female with healthy
non-consanguineous parents (Fig. 1). Beginning at the age
of 20, she developed weakness in the lower limbs, accom-
panied by spasticity which was not alleviated by treatment
with baclofen. She is cognitively impaired, advancing in her
education only until middle school. MMSE and MoCA
scores were 23/30 and 15/30, respectively (impaired in exe-
cution, calculation and delayed memory). Upon examin-
ation, she had mild dysarthria, bilateral patellar clonus,
positive Babinski’s sign, pes cavus (Fig. 2) and a scissors
gait. Upper extremities were apparently normal. Blood and
CSF testing showed no marked abnormalities. EMG re-
vealed neurogenic, mild axonal sensory-motor neuropathy,
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especially in lower extremities. Brain MRI revealed extreme
thinning of corpus callosum, particularly in the anterior
region (Fig. 3a). Thoracic MRI showed remarkable atrophy
of thoracic spinal cord (Fig. 3b).
Her sister (II-1) is a 33-year old female with a similar,
but more severe clinical phenotype with an 18 year his-
tory of disease. She is bedridden and severely handi-
capped due to the disturbance in her gait. She has severe
cognitive impairment and did not progress past an elem-
entary school education.
Genomic DNA was extracted from peripheral blood
samples according to standard procedures. SPG11 was
screened for mutations by PCR amplification using pre-
viously described primer pairs [4] followed by Sanger
sequencing of the amplicons (Additional file 1). In the
two affected individuals, compound heterozygous muta-
tions were identified in the SPG11 gene: c.1551_1552delTT,
p.Cys518SerfsTer39 in exon 7; and c.5867-1G >T (IVS30-
1G >T), p.Thr1956ArgfsTer15, a splice site mutation in
intron 30 (showed in Fig. 4). Segregation of the genetic vari-
ants was validated in the other family members: the father
(I:1) carried c.1551_1552delTT in the heterozygous state,
while the mother (I:2) and the middle sister (II:2) carried
c.5867-1G >T (IVS30-1G >T) in the heterozygous state
(see Fig. 1). Both parents and the middle sister showed no
symptom of spasticity or cognitive deterioration. The
c.1551_1552delTT is novel but is similar to two previously
described, nearby deletion mutations at c.1550_1551delTT
(rs312262730) and c.1549_1550delCT (rs312262730), both
of which are associated with SPG11 phenotypes. The
second mutation, c.5867-1G >T (IVS30-1G >T), is also
novel. Neither of these mutations was detected in 100 unre-
lated healthy Chinese control individuals or in the 1000
Genomes database.
Bioinformatic analysis of these mutations is predicted to
prematurely truncate the protein product. The c.1551_
1552delTT mutations causes a frameshift at amino acid
reside 518 resulting in a premature stop codon (p.Cys51
8SerfsTer39). Such a mutation would result in a truncated
protein but more likely would result in reduced transcript
levels due to non-sense mediated decay. Similar mutations
have been described in other cases of SPG11 [5]. The
second mutation alters the consensus AG sequence at the
Fig. 1 Family pedigree of non-conanguineous parents indicating
segregation of SPG11 mutations. Squares, male; circles, female; filled
circle, affected female; arrow, proband
Fig. 2 Presentation of pes cavus in the index patient (II:3)
Fig. 3 Sagittal brain and thoracic spinal MRI image in index patient
(II:3). a: Brain MRI shows thinning of corpus callosum, emphasized in
the anterior part with a “beaked” shape (arrow). Ther is no obvious
periventricular or deep cerebellar white matter lesions and no obvious
cerebral or cerebellar atrophy. b: Throracic spinal MRI shows thinning
of the thoracic spinal cord with volume loss but no obvious signal
abnormalities in the cord
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3′ acceptor site of intron 30 (c.5867-1G>T (IVS30-1G>T)).
Splice site predictions using the mutated sequence were
performed using Splice Site Prediction by Neural Net-
work (http://www.fruitfly.org/seq_tools/splice.html) and
NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/).
Both analysis programs predict a complete abolishment
of splicing using the mutated 3′ acceptor site. Thus, we
predict exclusion of exon 31 from the transcript result-
ing in a frameshift and premature stop codon shortly
downstream (p.Tyr1956ArgfsTer15). Similar to the above
mutation, this would likely result in a truncated protein or
alternatively may result in reduced transcript levels due to
nonsense mediated decay, suggesting a possible loss of
function mechanism (Fig. 5).
Fig. 4 Sanger sequencing of exon 7 (c.1551_1552delTT) containing a TT deletion in SPG11 in an affected individual (a) and unaffected individual (b).
Sanger sequencing of a splice site mutation (c.5867-1G > T (IVS30-1G > T)) in intron 30 of SPG11 in an affected individual (c) and control, unaffected (d)
Fig. 5 Bioinformatic prediction of the SPG11 protein structure in the presence of the found mutations. Boxes in blue indicate the exons of the SPG11
major transcripts (NM_025137 and NM_001160227). The location of the mutations described in this study are located in exon 7 (c.1551_1552delTT)
and upstream of exon 31 (c.5867-1G > T (IVS30-1G > T)). Boxes in grey indicate the predicated protein truncations (middle and lower) as compared with
a full-length wild-type structure (upper)
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Conclusions
We identified novel compound heterozygous mutations in
SPG11 in a Chinese HSP-TCC family (c.1551_1552delTT
and c.5867-1G > T (IVS30-1G > T)). Our patients pre-
sented with typical clinical symptoms of ARHSP-TCC
which included spastic paraplegia, cognitive impairment,
peripheral neuropathy and distal musle atrophy. Thinning
of thoracic spinal cord in our index patient is likely the
result of degeneration of long corticospinal tracts and is
usually present in nearly all subtypes of the HSP, mostly at
later disease stages [6, 7].
Mutations in SPG11 are found in the majority of re-
ported complex ARHSP-TCC cases with TCC being the
single best indicator for SPG11 [2]. Another Chinese
family with ARHSP-TCC was reported previously, the
index patient presented with prominent intellectual dis-
ability rather than spasticity had different compound
heterozygous mutations of SPG11 [8]. For patients pre-
senting with HSP-TCC, SPG11 should be screened ini-
tially once infectious causes are eliminated. Other SPG
loci including SPG15, SPG35 and SPG48 should be con-
sidered if no mutations in SPG11 are discovered [9].
Interestingly, mutations in SPG11 can also cause other
disorders, such as juvenile amyotrophic lateral sclerosis
(ALS5) [10], juvenile Parkinsonism [11], and autosomal
recessive axonal Charcot-Marie-Tooth disease [12]. Thus,
SPG11 mutations have an wide phenotypic spectrum sug-
gesting that additional care should be taken when examin-
ing HSP patients. In summary, we demonstrate the
importance of screening the SPG11 gene in the ARHSP-
TCC patients and have provided additional clinical pheno-
types resulting from mutations in the SPG11 gene.
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